Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.

Learn more about:
Related Clinical Trial
Colorado-Oregon Altitude Study The Effects of Intermittent Hypoxia on Acute Hypoxic Injury Effect of Isocaloric Ketogenic Diet on Physical Performance at High Altitude The Pre-acclimatization Augmented Extreme Altitude Expedition Effect of Altitude on Iron Absorption in Iron Depleted Women Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD HIGH Altitude CArdiovascular REsearch Latin America Population Study Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance Iron Status and Cardiopulmonary Physiology Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude The Psychophysiological Effect of Simulated and Terrestrial Altitude Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude AZ, MZ, and the Pulmonary System Response to Hypoxia Study of the Effects of Iron Levels on the Lungs at High Altitude Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort Three New Ideas to Protect Special Forces From the Stress of High Altitude Breathing Training to Improve Human Performance at High Altitude Oxidative Stress in Hypobaric Hypoxia Safety Evaluation of Aminophylline and Methazolamide Decompression Tables for Diving at Altitude Chronic Mountain Sickness, Systemic Vascular Function Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Inhaled Budesonide for Altitude Illness Prevention Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Drug Combination on Exercise Performance at High Altitude Acclimatization Mechanisms During Ascent to 7500m Prevention of Acute Mountain Sickness by Intermittent Hypoxia Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Training in Hypoxia to Prevent Acute Mountain Sickness Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness Inhaled Budesonide and Acute Mountain Sickness Altitude Sickness Prevention and Efficacy of Comparative Treatments Alternative Treatments in Acute Mountain Sickness Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Brief Title

Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.

Official Title

Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.

Brief Summary

      Low oxygen at altitude causes pauses in breathing during sleep, called central sleep apnea.
      Central sleep apnea causes repeated awakenings and poor sleep. Low oxygen itself and the
      induced oxidative stress can damage mental function which is likely worsened by poor sleep.
      Reduced mental function due to low oxygen can pose a serious danger to mountain climbers.
      However there is also mounting evidence that even in populations of people that live at high
      altitudes and are considered adapted, low oxygen contributes to reductions in learning and
      memory. Therefore there is a serious need for treatments which may improve sleep, control of
      breathing and mental function during low oxygen. Melatonin is a hormone produced in the brain
      during the night which regulates sleep patterns with strong antioxidant and anti-inflammatory
      properties. A study previously reported that melatonin taken 90 mins before bed at 4,300 m
      (14,200 ft) induced sleep earlier, reduced awakenings and improved mental performance the
      following day. However how melatonin caused these effects was not determined. Therefore this
      study aims to determine how melatonin effects control of breathing, sleep and mental
      performance during exposure to low oxygen.
    


Study Phase

Early Phase 1

Study Type

Interventional


Primary Outcome

Neurocognitive function


Condition

Altitude Hypoxia

Intervention

Melatonin

Study Arms / Comparison Groups

 Normoxia
Description:  Sleep in normal room air with no drug

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Dietary Supplement

Estimated Enrollment

20

Start Date

July 4, 2017

Completion Date

December 20, 2018

Primary Completion Date

December 20, 2018

Eligibility Criteria

        Inclusion Criteria:

        -

        Exclusion Criteria:

          -  Sleep disorders

          -  Pregnant females

          -  Smokers (quit ≥ 1 year ago acceptable)

          -  Any known cardiac (apart from treated hypertension with acceptable drugs, see below),
             pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular,
             hepatic disease, or patients with diabetes.

          -  Prior or current use of melatonin.

          -  Use of any medications that may affect sleep or breathing, blood-thinning medications
             (anticoagulants), antioxidants, anti-inflammatories, medications that suppress the
             immune system (immunosuppressants), diabetes medications and birth control pills.

          -  A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar
             disorder, major depression, panic or anxiety disorders.

          -  Substantial alcohol (>3oz/day) or use of illicit drugs.

          -  Previous occurrence of high altitude pulmonary or cerebral edema.

          -  Recent exposure to altitude (>8000ft) in the last month or having slept at an altitude
             >6000ft in the last month.

          -  Inability to provide written informed consent or able to complete the experiment.

          -  Non-English speakers (necessary to complete neurocognitive testing).

          -  More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day.
      

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03368352

Organization ID

170200


Responsible Party

Principal Investigator

Study Sponsor

University of California, San Diego


Study Sponsor

, , 


Verification Date

January 2019